Clinical research studyChanges in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management
Section snippets
Study
Four nationwide French registries were conducted 5 years apart from 1995 to 2010: USIK 1995,17 USIC 2000,18 French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarction (FAST-MI) 2005 (NCT00673036),19 and FAST-MI 2010 (NCT01237418).20 The methods used have been described previously.17, 18, 19, 20 Briefly, their primary objectives were to evaluate the characteristics, management, and outcomes of acute myocardial infarction patients, as seen in routine clinical practice, on a
Study Population
There were 3389 elderly patients enrolled in the 4 surveys (Table 1). The proportion of elderly patients remained stable over time in non-ST-elevation myocardial infarction patients (1995: 36.4%, 2010: 38.4%), but decreased in ST-elevation myocardial infarction patients (1995: 29.9%, 2010: 25.5%). Mean age remained stable; among risk factors, hypertension, diabetes, obesity, and hypercholesterolemia increased. Previous myocardial infarction remained stable while history of myocardial
Discussion
In this study, early and 1-year mortality in elderly patients admitted for acute myocardial infarction decreased by 50% in the past 15 years. Mortality decrease was observed in all age classes, including the very elderly, and was related to both improved 30-day survival and, to a lesser extent, improved survival beyond 30 days. Both increased use of early percutaneous coronary intervention, use of alternative anticoagulants instead of unfractionated heparin and early use of recommended
Conclusions
One-year mortality of elderly patients with acute myocardial infarction has decreased by 50% in the past 15 years in France, mainly driven by a strong reduction in early mortality. Changes in early management seem more determinant than changes in population characteristics to explain this reduction. These data, also observed in the population of very elderly individuals, therefore strongly suggest that it is reasonable to apply the recommendations drawn from randomized trials performed in
Acknowledgment
The authors are deeply indebted to all patients and physicians participating in the surveys.
References (33)
- et al.
Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006
Am Heart J
(2008) - et al.
Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years
Int J Cardiol
(2014) - et al.
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE)
Am Heart J
(2005) - et al.
Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results
J Am Coll Cardiol
(1997) - et al.
Encouraging trends in acute myocardial infarction survival in the oldest old
Am J Med
(2013) - et al.
Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome)
JACC Cardiovasc Interv
(2012) - et al.
Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry
Int J Cardiol
(2013) - et al.
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Lancet
(2002) - et al.
Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008
Circulation
(2012) - et al.
Population trends in the incidence and outcomes of acute myocardial infarction
N Engl J Med
(2010)
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006
JAMA
Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction
JAMA
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction
JAMA
Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study
BMJ
Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010
Eur Heart J
Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology
Circulation
Cited by (0)
Funding: USIK 1995 was funded by Laboratoire Roussel, which was involved in the design and conduct of the study, as well as data collection and management. USIC 2000 was funded by Aventis-France, which was involved in the design and conduct of the study, as well as data collection and management. FAST-MI 2005 and FAST-MI 2010 are registries of the French Society of Cardiology. FAST-MI 2005 was supported by unrestricted grants from Pfizer and Servier, and an additional grant from the Caisse Nationale d'Assurance Maladie-Travailleurs Salariés. FAST-MI 2010 was supported by unrestricted grants from AstraZeneca, the Daiichi-Sankyo-Eli-Lilly alliance, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis. None of the companies had a role in the design and conduct of the study, data collection, or management. They were not involved in the analysis and interpretation of the data, nor in the preparation, review, or approval of the manuscript.
Conflict of Interest: EP reported speaker, board membership, and consulting fees: Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Lilly, MSD, Sanofi-Aventis. NA reported speaker fees: Astra Zeneca. GC reported grants to the Institution or Consulting/lecture fees from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston, Biotronik, BMS, Daiichi Sankyo, Eli-Lilly, Europe, Fédération Française de Cardiologie, Fondation Coeur et recherche, Medtronick, MSD, Pfizer, Sanofi-Aventis, The Medicines Company. DB reported lectures and consulting fees for Edwards LifeSciences. ME reported research grants to the Institution from Boston Inc or Symposia and consulting fees from Bayer, Jansen Cilag, Bristol-Myers-Squibb, Pfizer, AstraZeneca, Daiichi-Sankyo. PH reported disclosures from Astra-Zeneca and Bayer. FS reported receiving grant support to his institution and travel support for scientific meetings: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS Daiichi–Sankyo, Lilly, Medtronic, Merck, Pfizer, Sanofi Aventis, and Servier. JF reported receiving grants and speaker fees: Amgen, MSD and Sanofi. TS reported institutional grants from AstraZeneca, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, and Pfizer; personal fees from board membership, consultancy, or lecture from AstraZeneca, Astellas, Bayer, BMS, Lilly, MSD, and Sanofi. ND reported receiving research grants: AstraZeneca, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Pfizer, Sanofi Aventis, Servier, and The Medicines Company; and advisory panels or lecture fees: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Menarini, Merck-Serono, Novo-Nordisk, Servier, and Sanofi Aventis. ER, AL, MM, OS-J, PJ, VB, ED, and GM reported no conflicts of interest for the present study.
Authorship: All authors had access to the data and played a role in writing this manuscript.